A prospective clinical and radiological study of incidental cerebral small vessel disease: Aspirin versus Cilostazol (PACCS)
- Conditions
- Nervous System Diseases
- Registration Number
- PACTR202301861240705
- Lead Sponsor
- Hany Aref
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 220
Patient aged 45 or Above suffering from incidental cerebral SVD
Patients presenting with slowly progressive cognitive, urinary, gait abnormalities and/or depression, rather than acute stroke presentation.
MRI brain suggestive of small vessel disease in the form of deep white matter hyperintensities (WMH), lacunes, cerebral microbleeds, enlarged Virchow spaces, silent small subcortical infarct
? Patients with acute onset stroke of any source (Ex: CADASIL)
? Patients with past history of acute large vessel stroke
? Patients with large vessel occlusion or stenosis >50%
? Contraindication to MRI (as pacemakers or metal plates and screws)
? Alcohol addiction or substance abuse (to exclude substance induced vasculitis)
? Any neurological disease affecting white matter (eg; Multiple sclerosis, sarcoidosis, etc),
? Any neurological disease presenting with symptoms similar to cerebral small vessel disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Describe Progression of lesions in MRI after one year of receiving single antiplatlet;Explore the progression of the white matter intensities, lacunes, microbleeds and brain atrophy in the studied groups.;Assess the difference in cognitive performance, gait and sphincteric affection in SVD patients between the intervention groups (aspirin versus cilostazol).
- Secondary Outcome Measures
Name Time Method Assess side effects of aspirin versus ciolstazol in patients with incidental cerebral small vessel disease